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Introduction
The design and biofabrication of nanoscale materials that mimic viral properties (such as self-assembling, cell surface receptor binding, internalization and proper intracellular trafficking) is highly promising for targeted drug delivery and gene therapy 1 . Proteins are among the most convenient materials for the generation of functional building blocks in nanoparticle construction [2] [3] [4] [5] . This is not only linked to protein functionalities but also to the fact that their spatial conformation, potential for cross-interactions and supramolecular organization can be designed and adjusted by simple genetic engineering. In addition, cost-effective biofabrication of proteins for therapeutic applications has been fully demonstrated in Bio-Pharma, and the emergence of novel cell factories and the implementation of genetic and systems approaches expand the opportunities for the biosynthesis of difficult proteins [6] [7] [8] . Then, while protein production and downstream are technically solved issues, the bases for a rational engineering of protein-protein cross molecular interactions remain to be fully established.
Some architectonic principles have been proposed for the construction of peptide-based nanofibers and nanoparticles 4 , exploiting the amphiphilic character of chemically modified short peptides 9 or the self-assembling properties of the β-sheet-rich amyloidal protein domains 10 . Regarding long-lengthen proteins 4 suitable for biological production, the engineering of natural oligomerization domains into modular polypeptides has allowed the construction of protein nanoparticles based on hybrid fusion proteins acting as building blocks 11 . Of course, the production of structural viral proteins renders, in some cases, complex structures known as virus like particles (VLPs) that architectonically mimic the natural viral capsid versions. While largely proved to be excellent immunogens, the usability of VLPs and other nanostructured materials as vehicles for drug and nucleic acid delivery is rather narrow 12 . This is because the limited versatility in the design of nanoscale physical properties and biological functions of the resulting nanoparticles, and on the other side, by the still partial comprehension of the mechanics of the cross-molecular interactions that govern the formation of stable supramolecular complexes.
Recently, we have proposed a nanoscale architectonic principle that permits the generation of protein nanoparticles in which structurally unrelated protein species can act as building blocks 13 . When tagged with a cationic amino terminal peptide and a polyhistidine tail at the carboxy terminus, these scaffold proteins (eg. GFP, IRFP, p53 and Hsp 70), cross-interact by electrostatic interactions and form toroid structures stabilized by a complex set of alternative forces, including van der Wals and hydrogen bond interactions 14 . These nanoscale materials, of regulatable size, allow the intracellular delivery of functional proteins to specific target cells and tissues upon systemic administration [14] [15] [16] . (Table 1) were designed in house and obtained from Genscript (Piscataway, USA). The synthetic genes (Seq-1-7-GFP-
H6, Seq-1-8-GFP-H6, Angiopep-2-7-GFP-H6 and Angiopep-2-8-GFP-H6)
were then inserted into the prokaryotic expression commercial pET22b vector (#69744-3, Novagen, USA) using NdeI/HindIII restriction sites. Escherichia coli BL21 (DE3) cells were transformed with recombinant pET22b plasmids by heat shock (45 sec, 42ºC) to allow protein production.
Protein production and purification. Bacterial cells carrying the appropriate plasmid vector were cultured in 2L shaker flasks with 500 ml of LB (Luria-Bertani, Conda Cat. 1551.00) medium containing 100 μg/ml ampicillin, at 37 ºC until the OD 550 reached 0.5-0.7. 
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Results

Protein design, production and characterization. Angiopep-2-GFP-H6
and Seq-1-GFP-H6 are modular proteins displaying low density lipoprotein receptor (LDLR) ligands at their amino termini (Angiopep-2 and Seq-1 respectively) (Table 1) , that reach the brain upon systemic administration 17 . Both Angiopep-2 and Seq-1 are well known BBBcrossing peptides proven useful as brain-homing agents in drug delivery 18, 19 . At difference of the related construct ApoB-GFP-H6 that 13 form nanoparticles of 18 nm in diameter 17 , these proteins do not show any self-assembling activity and remain monomeric. In an attempt to upgrade Angiopep-2-GFP-H6 and Seq-1-GFP-H6 polypeptides up to self-assembling building blocks for nanoparticle construction, arginine-and lysine-containing stretches were designed for their introduction in both proteins, between the ligand and the linker to the scaffold GFP (Table 1, 
Interestingly, high magnification TEM images of Seq-1-8-GFP-H6
showed an architectonic scheme (a circular electrodensity pattern) compatible with a toroid organization, similar to that recently shown for the related protein T22-GFP-H6 14 . This particular geometry was fully confirmed by high resolution FESEM analysis of the same samples (Figure 1 E) . As expected, no nanoparticles but some unspecific aggregates with different shape and size were observed when examining Seq-1-7-GFP-H6 samples (Figure 1 C) . As shown in Figure 1A , none of the Angiopep-2-GFP-H6-derived proteins formed nanoparticles.
In vitro analysis of cellular internalization. At this stage, we were interested in the biological characterization of Seq-1-8-GFP-H6 nanoparticles regarding their ability to penetrate target cells, and especially in comparison with the closely related, unassembled protein Seq-1-7-GFP-H6 that only differs by a single missing arginine residue ( Table 1 ). Before that, we determined that the fluorescence of However, while the amount of monomeric GFP-H6 and Seq-1-7-GFP-H6 dramatically decreased from 30 min to 2 h post administration, as expected for materials ≤ ~8 nm in size, Seq-1-8-GFP-H6 nanoparticles remained in kidney for longer times ( Figure 5C ). This fact suggested issues additional to size-dependent filtration as contributors in regulating its occurrence in kidney.
Discussion
By using empirical information from of a set of closely related proteins with and without self-assembling properties 25 , we have designed and constructed protein-only nanoparticles containing the Seq-1 BBBcrossing peptide (Figure 1 ). This has been done by the addition of several cationic peptides at the amino terminus of the modular protein Seq-1-GFP-H6 (Table 1) , a polypeptide that exclusively remains in unassembled form (Figure 1) . A similar attempt to engineer the self-assembling of Angiopep-2-GFP-H6 failed (Figure 1 ) probably because the more scattered distribution of cationic residues (Table 1 ).
This would result in a less polar splitting of the electrostatic charges necessary for the assembling of building blocks [13] [14] [15] . In fact, one additional cationic lysine residue in Seq-1-8-GFP-H6 compared to Seq-1-7-GFP-H6 was sufficient to efficiently triggering self-assembling (Table 1, Figure 1 ). Seq-1-8-GFP-H6 nanoparticles exhibited the expected size of 30 nm (Figure 1 A) , a toroid organization (Figure 1 C, E) and a higher cellular penetrability into LDLR + HeLa cells when compared with the unassembled Seq-1-7-GFP-H6 version (Figure 2, 3) .
In addition, the transcytic properties of Seq-1-8-GFP-H6, measured in a CaCo-2-based test 24 , were clearly superior to those exhibited by the unassembled form Seq-1-7-GFP-H6 (Table 2) . Since the mere addition of cationic peptides to pre-existing protein nanoparticles did not alter cell penetrability per se 26 , the formation of nanoparticles rather that the single amino acid addition in Seq-1-8-GFP-H6 would be responsible for enhanced cell penetrability. A higher penetrability of protein nanoparticles compared with individual building blocks is in agreement with previous results obtained in our laboratory 27 and it is probably related with the multivalent presentation of the cell ligands (Seq-1, in the present case) on the surface of nanoparticles that favours endosomal entrapment 28 . The endosomal route of Seq-1-8-GFP-H6 nanoparticle uptake is confirmed by the strong merging signals (yellowish spots, merging green and red) observed in in vivo internalization assays (Figure 3 In this study, we have engineered the brain-targeted polypeptide Seq-1-GFP-H6 to self-assemble into regular, protein-only nanoparticles formed by multiple copies of the resulting protein Seq-1-8-GFP-H6.
Seq-1-8-GFP-H6 differs from the parental protein by 7 cationic residues that were inserted into a permissive region of the protein, between the Seq-1 peptide and the core GFP ( Table 1) . The resulting fluorescent nanoparticles show a dramatic improvement of cell penetrability and transcytic activities in vitro regarding monomeric versions, but contrarily, the brain targeting properties did not result improved by the multimerization (Figure 4) . The engineering principle developed here should permit the construction of protein-based nanoparticles by the precise sequence manipulation of pre-existing proteins that increase, in a controlled way, the cationic load of the amino terminal regions. Also, the progressive developments in systems and genetic approaches to recombinant protein production 40 increasingly facilitate protein engineering, biofabrication in cell factories 41 and downstream 41, 42 . In the current bubbling context of novel protein drugs of interest in cancer therapies and for other conditions 44 , formulating such therapeutic proteins as nanoparticles would offer an interesting engineering tool with a broad applicability in nanomedicine, as the multivalent presentation of homing agents in those materials, either natural or added, is expected to dramatically enhance cell uptake.
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